Evidence map›Paper›PMID 40353902›Full record

Trial reportClinical and experimental medicine2025

Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial.

Huacong Cai, Jishi Wang, Zhenyu Yan, Hu Zhou, Zhenyu Li, Feng'e Yang, Pengxiang Guo, Da Gao, Jie Jin, Yun Zeng and 1 more

Abstract readMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huacong Cai *Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jishi Wang *Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Zhenyu YanNorth China University of Science and Technology Affiliated Hospital, Tangshan, China.
Hu ZhouHenan Cancer Hospital, Zhengzhou, China.
Zhenyu LiThe Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Feng'e YangFujian Medical University Union Hospital, Fuzhou, China.
Pengxiang GuoGuizhou Provincial People's Hospital, Guiyang, China.
Da GaoThe Affiliated Hospital of Inner Mongolia Medical University, Huhetaote, China.
Jie JinThe First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yun ZengFirst Affiliated Hospital of Kunming Medical University, Kunming, China.
Shujie WangChinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. WangShujie11@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 10

Indexed as

Immunoglobulins, IntravenousPurpura, Thrombocytopenic, IdiopathicAdolescentAdultAgedChinaEast Asian PeopleFemaleHumansMaleMiddle AgedPlatelet CountTreatment OutcomeYoung AdultImmunoglobulins, IntravenousBleeding assessmentImmune thrombocytopeniaIntravenous immunoglobulinPlatelet countResponse

Identifiers

PMID40353902
PMCPMC12069505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.